Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib, Toripalimab, and Chemotherapy in RAS/BRAF Mutant MSS Colorectal Cancer
NCT04653480Phase 2Unknown
- Sponsor
- Zhejiang University
- Start
- Feb 2021
- Primary completion
- Jun 2025
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib, toripalimab in colorectal cancer (CRC), sponsored by Zhejiang University. Status: unknown.
02
Drugs
surufatinibtoripalimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04653480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04653480.